about
sameAs
LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in miceHepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathwayBone marrow p16INK4a-deficiency does not modulate obesity, glucose homeostasis or atherosclerosis developmentDownregulation of the tumour suppressor p16INK4A contributes to the polarisation of human macrophages toward an adipose tissue macrophage (ATM)-like phenotypeThe multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages.Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaBPeroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets.Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs?Cdkn2a/p16Ink4a regulates fasting-induced hepatic gluconeogenesis through the PKA-CREB-PGC1α pathway.Chromatin recruitment of activated AMPK drives fasting response genes co-controlled by GR and PPARα.Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity.The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha.Inhibition of JNK by HGF/SF prevents apoptosis induced by TNF-alpha.PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.The tumour suppressor CDKN2A/p16INK4a regulates adipogenesis and bone marrow-dependent development of perivascular adipose tissue.The logic of transcriptional regulator recruitment architecture at cis-regulatory modules controlling liver functions.Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties.Circumventing glucocorticoid-mediated hyperinsulinemia via the activation of PPARalpha.Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects.Thioredoxin-1 and its natural inhibitor, vitamin D3 up-regulated protein 1, are differentially regulated by PPARalpha in human macrophages.Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice.Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway.O89 Suppression of the tumour suppressor p16ink4a drives human macrophages towards a phenotype resembling adipose tissue macrophages (ATMs)Peroxisome Proliferator-Activated Receptors Mediate Pleiotropic Actions of StatinsTh-W60:3 Acute anti-inflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the PKC signalling pathwayThe RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed DyslipidemiaInvolvement of RAS-ERK signaling in multiple biological responses to HGF/SF
P50
Q24316352-0C172663-0433-4048-B72B-0141EC7276C8Q28214429-02641893-AB1B-41CE-8663-EA596AE9A166Q28731544-0346CDA1-6E77-444E-A093-470339CF18EAQ33610073-2BFC56AA-4907-4021-A355-F934CBF78232Q36843122-AF7D5397-C13D-438D-A577-7CF2ED6D8A6FQ36916423-ABFB85D5-F670-4685-A593-5BEDE791CD12Q37147426-A52FF6C6-CF56-4073-B381-C75B04B363F0Q37183113-B4628861-9F8F-41B1-A0DE-D43CBDDE0C76Q38312834-0F4B7038-46F3-4B28-8B1A-EB96D797893BQ38368484-55C5850D-9F96-4AEB-92EB-7FF451F12DDEQ38999261-F92CAAC3-9E87-447A-B01A-E18B9037D0ACQ39439403-D7007A51-39BC-4575-B049-9CFABC5A6656Q39945904-75EC6909-7AE6-4A23-BB5E-FFC06C9695CDQ40558254-1C270ED2-0B70-4545-A5AD-CED6475AD4C1Q40576310-21522CAF-B14A-427E-B6F4-D55398B10C54Q41374973-EF186029-F827-4491-BED4-B36077AEF0FBQ42649980-9B936DFB-6BB4-4311-8584-D0A4A5D7426BQ45054466-9F9A6DC3-5557-4910-B2D6-0DD67A513DFFQ45148001-D46258F8-A078-4108-AA35-CB500CA47BB6Q45922637-C62EDD26-D586-4388-9851-E67F669E4AD4Q46302614-BC7C28B5-473F-452F-94FA-B1864D20E7A5Q46320794-F96272E0-3442-46D5-A0DB-848B70463844Q46322918-6CE4DEDE-16DE-42E3-8A18-479D04BD6F94Q46882606-BC9AB208-5056-41D2-9657-350EF774B107Q57244130-B0F539C6-7F3F-40EA-9207-60FCB17770C1Q57244210-600F206B-0025-4768-BA9F-4E2B6A6DFF3BQ57244214-74E08622-40AD-486A-A260-B9FD30B1EEE6Q57244233-C57DF07D-BC33-4B36-AA47-0CFF9BC9350EQ78673892-90FCF6FF-9F02-4A98-84FA-C3776F3A5F5D
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Réjane Paumelle
@ast
Réjane Paumelle
@en
Réjane Paumelle
@es
Réjane Paumelle
@nl
type
label
Réjane Paumelle
@ast
Réjane Paumelle
@en
Réjane Paumelle
@es
Réjane Paumelle
@nl
altLabel
R Paumelle
@en
prefLabel
Réjane Paumelle
@ast
Réjane Paumelle
@en
Réjane Paumelle
@es
Réjane Paumelle
@nl
P106
P21
P31
P496
0000-0002-4489-0717